{"organizations": [], "uuid": "5b51891a36be3539c26d9f0f8b6b556dd7c4daea", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180308.html", "section_title": "Archive News &amp; Video for Thursday, 08 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-innate-pharma-fy-net-results-swing/brief-innate-pharma-fy-net-results-swings-to-loss-of-48-4-million-euros-idUSW8N1KI009", "country": "US", "domain_rank": 408, "title": "BRIEF-Innate Pharma FY Net Results Swings To Loss Of 48.4‍​ Million Euros", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.998, "site_type": "news", "published": "2018-03-08T14:26:00.000+02:00", "replies_count": 0, "uuid": "5b51891a36be3539c26d9f0f8b6b556dd7c4daea"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-innate-pharma-fy-net-results-swing/brief-innate-pharma-fy-net-results-swings-to-loss-of-48-4-million-euros-idUSW8N1KI009", "ord_in_thread": 0, "title": "BRIEF-Innate Pharma FY Net Results Swings To Loss Of 48.4‍​ Million Euros", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-innate pharma", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 8 (Reuters) - INNATE PHARMA SA:\n* FY REVENUE AND OTHER INCOME EUR 44.0‍​ MILLION VERSUS EUR 65.7 MILLION YEAR AGO\n* FY OPERATING LOSS EUR 40.0‍​ MILLION VERSUS INCOME EUR 7.6 MILLION YEAR AGO\n* FY NET LOSS EUR 48.4‍​ MILLION VERSUS INCOME EUR 12.6 MILLION YEAR AGO\n* CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS AMOUNTED TO EUR 176.6 MILLION AS OF DEC. 31\n* IPH5401 WILL ENTER FIRST CLINICAL STUDIES IN ONCOLOGY IN 2018\n* EXPECTS CLINICAL READ-OUTS FOR BOTH MONALIZUMAB AND IPH4102 PROGRAM IN 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-08T14:26:00.000+02:00", "crawled": "2018-03-09T14:39:09.000+02:00", "highlightTitle": ""}